Published in:
Open Access
01-12-2014 | Research article
Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model
Authors:
Justyna M Starczewska Amelio, Javier Cid Ruzafa, Kamal Desai, Spiros Tzivelekis, Dominic Muston, Javaria Mona Khalid, Philip Ashman, Andrew Maguire
Published in:
BMC Cancer
|
Issue 1/2014
Login to get access
Abstract
Background
The prevalence of patients with gastrointestinal stromal tumourgst (GIST) who fail currently available treatments imatinib and sunitinib (third-line treatment-eligible GIST) is unknown, but is expected to be below an ultra-orphan disease threshold of 2/100,000 population used in England and Wales. Our study was designed to estimate the prevalence and absolute number of UK patients with unresectable/metastatic GIST at first-, second- and eventually third-line treatment.
Methods
Our open population model estimates the probability that the prevalence of UK third-line treatment-eligible GIST patients will remain under the ultra-orphan disease threshold. Model parameters for incidence, proportion of unresectable/metastatic disease and survival estimates for GIST patients were obtained from a targeted literature review and a UK cancer register. The robustness of the results was checked through differing scenarios taking extreme values of the input parameters.
Results
The base-case scenario estimated a prevalence of third-line treatment-eligible GIST of 1/100,000 and a prevalence count of 598 with a 99.9% likelihood of being below the ultra-orphan disease threshold. The extreme scenarios, one-way and probabilistic sensitivity analyses and threshold analysis confirmed the robustness of these results.
Conclusions
The prevalence of third-line treatment-eligible GIST is very low and highly likely below the ultra-orphan disease threshold.